Friday, July 20, 2018 9:37:53 AM
You missed this part of the article:
"it should be emphasized that eltrombopag is not likely to be a strong competitor (to Pluristem), since there is a lot more that needs to be done to repair the damage done by radiation."
The author of the article, Zach Hartman is PhD (biochemistry and molecular biology) and a very decent and intelligent observer of the biotech scene. When you leave out relevant information from the article, you undermine your argument (among other things).
An additional note: I see Novartis' interest as a POSITIVE! It shows that the target indications (multiple) represent a huge value. Pluristem will be there first and with a better product! How can I know this WITHOUT charts? Easy, look at the available data (as opposed to black magic).
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM